Skip to main
CLRBZ
CLRBZ logo

Cellectar Biosciences Inc Warrants 2016-8.4.21 on Shs (CLRBZ)


$0.00

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

Buy CLRBZ Stock

About Cellectar Biosciences Inc Warrants 2016-8.4.21 on Shs (CLRBZ)

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting ne...read more
Market cap
Today's volume
Revenue (TTM)
Avg. daily volume
EBITDA (TTM)
Open
Price / earnings ratio
Today's range
Debt / equity
52 week range
5 year debt / equity
Beta (LTM)
Interest coverage
Dividend & yield— (—)
Current ratio
Ex-dividend date
Next earnings
Dividend payable date

Frequently Asked Questions (FAQ)

How to buy CLRBZ stock on Public

  1. 1

    Sign up for a brokerage account on Public

    It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.

  2. 2

    Add funds to your Public account

    There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.

  3. 3

    Choose how much you'd like to invest in CLRBZ stock

    Navigate to the Explore page. Then, type CLRBZ into the search bar. When you see CLRBZ stock appear in the results, tap it to open up the purchase screen.

  4. 4

    Manage your investments in one place

    You can find your newly purchased CLRBZ stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets.

Buy CLRBZ Stock

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.